# India Radioligand Therapy Market

> India Radioligand Therapy RLT Market Research Report By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End User (Hospitals & Clinics, Diagnostic Centers, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.52%
- **2024:** $ 0.41 Billion
- **2025:** $ 0.44 Billion
- **2035:** $ 1 Billion
- **Key Players:** Bharat Biotech (IN), Dr. Reddy's Laboratories (IN), Laurus Labs (IN), Sun Pharmaceutical Industries (IN), Zydus Cadila (IN), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Siemens Healthineers (DE)

**Report ID:** MRFR/Pharma/50337-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** March 28, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-radioligand-therapy-market-52095

---

## Market Summary

## **India Radioligand Therapy RLT Market Overview**

As per MRFR analysis, the India Radioligand Therapy RLT Market Size was estimated at 372 (USD Million) in 2023. The India Radioligand Therapy RLT Market Industry is expected to grow from 410(USD Million) in 2024 to 1,020 (USD Million) by 2035. The India Radioligand Therapy RLT Market CAGR (growth rate) is expected to be around 8.638% during the forecast period (2025 - 2035)

**Key India Radioligand Therapy RLT Market Trends Highlighted**

The India Radioligand Therapy (RLT) market is witnessing significant growth driven by increasing cancer prevalence and advancements in nuclear medicine technology. The Indian government has been actively supporting the healthcare sector through initiatives like the National Health Mission, which aims to enhance cancer care services. 

This focus on improving cancer treatment accessibility serves as a key market driver, leading to greater adoption of RLT as a therapeutic option in patients suffering from various malignancies. Hospitals and clinics across India are increasingly investing in advanced radiotherapy equipment to provide cutting-edge treatment, further propelling the demand for radioligand therapies.

Recent trends indicate a growing preference for personalized medicine in oncology. This shift is evident as healthcare providers focus on tailoring treatments based on individual patient profiles, thus enhancing treatment efficacy and reducing adverse effects. Additionally, the rise of collaborations between domestic and international pharmaceutical companies aimed at developing innovative radioligand products is noteworthy. 

There is an opportunity for local manufacturers to explore partnerships with global firms for technology transfer and resource sharing, helping to accelerate the development of RLT solutions. Moreover, increased awareness through educational campaigns regarding the benefits of radioligand therapy is helping patients and healthcare professionals make informed decisions.

The Indian healthcare landscape is also witnessing a rise in research initiatives and clinical trials, which are essential for evaluating new RLT modalities. Overall, the combination of supportive government initiatives, innovation in treatment options, and growing awareness is driving the evolution of the RLT market in India, creating a robust platform for future growth and development.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Radioligand Therapy RLT Market Drivers**

**Increase in Cancer Incidence Rates**

'India Radioligand Therapy RLT Market Industry' is mostly driven by the country's increasing cancer rate. With an anticipated 1.16 million new cases recorded in 2018, the National Cancer Registry Program reports that the number of cancer cases has increased over the past ten years, and it is expected to continue to climb. In order to address this expanding healthcare issue, the Indian government's efforts to improve cancer care facilities and treatments are crucial. 

Significant progress in cancer treatment is being made by institutions like the Tata Memorial Centre and AIIMS (All India Institute of Medical Sciences), which is increasing demand for cutting-edge treatments like radioligand therapy and boosting market expansion. The 'India Radioligand Therapy RLT Market Industry' is likely to develop in tandem with the increasing incidence of malignancies, such as prostate and neuroendocrine tumours, which is anticipated to boost the use of radioligand therapy.

**Technological Advancements in Radioligand Therapy**

Rapid advancements in technology are a key driver of the 'India Radioligand Therapy RLT Market Industry'. Significant investments in Research and Development (R&D) by leading pharmaceutical companies like Sun Pharmaceutical Industries and Dr. Reddy's Laboratories are resulting in innovative treatment options that improve patient outcomes. The development of new radioisotopes and targeting agents has expanded treatment possibilities, increasing the efficacy of Radioligand Therapy.

The Department of Atomic Energy (DAE) in India is also actively involved in research related to radio pharmaceuticals, enhancing the capabilities of Radioligand Therapy. Such technological innovations are essential for catering to the growing needs of cancer patients in India, ultimately driving market growth.

**Government Initiatives and Support**

Government support is pivotal to the progression of the 'India Radioligand Therapy RLT Market Industry'. The Indian government has launched various health programs aimed at improving cancer care, such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS). This support is fostering a conducive environment for the expansion of Radioligand Therapy. 

Furthermore, investments in healthcare infrastructure and the establishment of cancer treatment facilities across major metropolitan areas by organizations like the Health Ministry are enhancing accessibility to advanced cancer therapies.The government's emphasis on reducing the cancer burden through early detection and advanced treatment options directly correlates with the market's growth potential.

**Increasing Awareness and Patient Preference for Targeted Therapies**

Growing awareness about targeted therapies is shaping the landscape of the 'India Radioligand Therapy RLT Market Industry'. There has been a notable rise in informational campaigns led by healthcare organizations and NGOs that highlight the benefits of Radioligand Therapy, leading to a more informed patient population. Recent surveys indicate that approximately 60% of cancer patients prefer targeted therapies over traditional treatments due to reduced side effects and improved quality of life.

Patients increasingly seek therapies that align with these preferences, and healthcare providers are responding by integrating Radioligand Therapy into their treatment protocols. Companies such as Theranostics Health and other innovators are also working to promote these new options, enhancing acceptance and ultimately driving market demand.

**India Radioligand Therapy RLT Market Segment Insights**

**Radioligand Therapy RLT Market Isotope Insights**

The Isotope segment of the India Radioligand Therapy Market showcases significant potential and differentiation within the broader landscape of therapeutic options, tailored specifically for precision medicine. As the healthcare sector in India embraces advanced treatment modalities, isotopes like Fluorine-18, Gallium-68, and Lutetium-177 are becoming increasingly vital due to their unique properties that facilitate targeted therapies. Fluorine-18 is predominantly used in positron emission tomography (PET) imaging and radiotherapy, enabling clinicians to visualize metabolic processes and detect tumors early, which is essential for improving patient outcomes.

Meanwhile, Gallium-68 is highly valued for its applicability in diagnosing neuroendocrine tumors through PET scans, allowing for precise treatment planning and monitoring. Lutetium-177 stands out in providing targeted radiation to tumors, especially in treating specific cancers like prostate and neuroendocrine tumors, thus driving demand in therapeutic applications. Each of these isotopes contributes uniquely to the evolving landscape of the India Radioligand Therapy Market, enhancing the effectiveness of treatment protocols. 

Furthermore, the versatility of these isotopes opens up opportunities for expanding their applications within cancer treatment, making them crucial for future advancements in this field.The broader market environment, coupled with rising healthcare expenditures and supportive government policies, creates a conducive atmosphere for growth and innovation within the India Radioligand Therapy Market. This sector is poised for impactful developments, particularly as research continues to explore novel applications and combinations of these isotopes in therapeutic frameworks.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Radioligand Therapy RLT Market Targeted Receptor Insights**

The Targeted Receptor segment within the India Radioligand Therapy RLT Market is witnessing notable advancements and interest from the healthcare sector, driven by rising cancer prevalence and the need for targeted treatment options. Essential receptors like Prostate-specific Membrane Antigen (PSMA) and Somatostatin Receptor (SSTR) play crucial roles in targeted therapies, particularly in prostate cancer and neuroendocrine tumors, respectively. Innovations in radionuclide therapy focusing on these receptors present promising avenues for treatment that can significantly enhance patient outcomes.

The Epidermal Growth Factor Receptor (EGFR) also holds significance, especially in addressing various solid tumors, thus expanding therapeutic possibilities within the Indian healthcare landscape. The heterogeneity of the market, indicated by the presence of diverse receptors, contributes to its overall growth, as different patient populations may respond distinctly to targeted therapies. Furthermore, government initiatives aimed at improving cancer care, along with increasing awareness about advanced treatment options, further solidify the prospects of the Targeted Receptor segment.Overall, the ongoing Research and Development in this area suggests a positive trajectory, offering new hope for cancer patients across India.

**Radioligand Therapy RLT Market Indication Insights**

The India Radioligand Therapy RLT Market is poised for notable growth in the Indication segment, showcasing significant advancements in targeted therapies for various types of cancers. Prostate cancer continues to be a focal point due to its high prevalence and the effectiveness of radioligand therapy in improving patient outcomes. Similarly, Neuroendocrine Tumors (NETs) represent a rapidly growing area, with rising awareness and diagnostic capabilities fueling demand for specialized treatment options. Breast cancer, another major concern, benefits from innovative therapies that enhance survival rates and minimize side effects, positioning it as a critical indication within the market.

The "Others" category encapsulates a range of conditions, highlighting the versatility of radioligand therapies in addressing diverse oncological needs. As government initiatives in India increasingly support cancer research and treatment advancements, the India Radioligand Therapy RLT Market data indicates a promising landscape, where targeted therapies are transforming the management of cancer. This trend reflects the broader shifts toward personalized medicine and improved therapeutic approaches, ensuring that patients receive more effective interventions tailored to their specific conditions.

**Radioligand Therapy RLT Market End User Insights**

The India Radioligand Therapy RLT Market exhibits a promising landscape within its End User segment, primarily comprising Hospitals and Clinics, Diagnostic Centers, and other related entities. Hospitals and Clinics play a pivotal role as they are often equipped with the necessary infrastructure and medical expertise to implement radioligand therapies effectively, thus significantly contributing to patient access and treatment outcomes.

Diagnostic Centers, on the other hand, are essential for early detection and diagnosis, ensuring timely interventions that are crucial for effective radioligand therapy.The integration of advanced imaging technologies in these centers aids in the precise localization of tumors, enhancing the efficacy of treatment regimens. 

Other categories within the End User segment further enrich the market's diversity by encompassing specialized facilities that cater to unique patient needs. With the increasing awareness and acceptance of radioligand therapies in India, particularly for conditions like cancer, there is a substantial opportunity for growth across these diverse segments. Furthermore, government initiatives aimed at improving healthcare infrastructure in India are expected to bolster the accessibility and adoption of radioligand therapies in various End User platforms.The ongoing advancements in technology, coupled with the rising prevalence of targeted therapies, are likely to facilitate significant progress in the India Radioligand Therapy RLT Market.

**India Radioligand Therapy RLT Market Key Players and Competitive Insights**

The India Radioligand Therapy (RLT) Market is marked by increasing interest due to its significant potential in treating various cancers through targeted therapy. This market represents a convergence of advancements in nuclear medicine and oncology, allowing for precise treatment options with minimal side effects. Competitive insights within this arena highlight the roles of key players who are contributing to the growth and development of RLT, showcasing their innovative approaches, strategic collaborations, and the quest for market expansion.

As the healthcare landscape in India evolves, companies are engaging in extensive research and development to build robust portfolios and enhance accessible treatment options for patients.

Bayer has established a concrete presence in the India Radioligand Therapy RLT Market by leveraging its extensive research capabilities and proven track record in pharmaceuticals. The company's strengths lie in its innovative portfolio, which includes advanced therapeutic solutions that address specific oncological patient needs. With a focus on strategic partnerships and collaborations in clinical research, Bayer actively works to enhance treatment outcomes through its targeted radioligand solutions. The company's commitment to improving patient care through tailored therapies and extensive post-marketing surveillance further cements its position as a formidable player in the radioligand landscape in India.

Lantheus Medical Imaging is recognized for its significant contributions to the India Radioligand Therapy RLT Market, especially with its key products that focus on diagnostics and therapeutic applications. The company’s innovative solutions cater specifically to the needs of oncology patients, providing targeted therapies that help in managing conditions more effectively. Lantheus Medical Imaging has been proactive in expanding its presence within India, adopting strategies that include collaborations with local healthcare providers and institutions to facilitate research initiatives. 

Furthermore, the company's focus on expanding its product portfolio through mergers and acquisitions demonstrates its commitment to strengthening its market position and addressing the evolving demands of the healthcare sector. Its investment in enhancing manufacturing capabilities and distribution networks also highlights the vision to lead in the field of radioligand therapy within the Indian market.

**Key Companies in the India Radioligand Therapy RLT Market Include**

**India Radioligand Therapy RLT Market Industry Developments**

In recent months, the India Radioligand Therapy (RLT) Market has witnessed significant developments, particularly in the area of investment and collaboration among key players. The market is driven by increasing incidences of cancer and the growing adoption of targeted therapies. Bayer has been expanding its footprint in India, focusing on enhancing treatment options available through RLT. Elekta announced advancements in their systems, aiming to streamline RLT delivery, which reflects a growth trend in patient-centered therapeutic approaches.

Health organizations in India, including Bharat Serums and Vaccines, have been investing in Research and Development to innovate new radioligands for better effectiveness against malignancies.

The last two years saw notable market growth, with the valuation increasing due to the introduction of new therapies and technology by companies like Lantheus Medical Imaging and Novartis. In July 2023, there was a strategic partnership announcement between Curium and Ipsen aimed at expanding their product offerings in the Indian RLT market. Moreover, government initiatives supporting cancer research are further enhancing growth prospects for the RLT sector. Overall, these trends indicate a robust investment landscape and a strong competitive environment in India's Radioligand Therapy market.

**India Radioligand Therapy RLT Market Segmentation Insights**

## Market Drivers

### Regulatory Support and Framework

The regulatory environment in India is becoming increasingly supportive of radioligand therapy, which is a crucial driver for the India [Radioligand Therapy Rlt](https://www.marketresearchfuture.com/reports/radioligand-therapy-rlt-market-11824) Market. The government has established guidelines to facilitate the approval and commercialization of radiopharmaceuticals. This regulatory support is essential for ensuring that innovative therapies can reach the market efficiently. Additionally, the establishment of clear protocols for clinical trials and patient safety standards is likely to encourage more research and development in the field of RLT. As regulatory frameworks continue to evolve, they will likely foster a conducive environment for the growth of the RLT market in India.

### Advancements in Radioligand Technology

Technological advancements in radioligand therapy are significantly influencing the India Radioligand Therapy Rlt Market. Innovations in radiopharmaceuticals and imaging techniques have improved the efficacy and safety profiles of RLT. For instance, the development of novel ligands that target specific cancer cells has shown promising results in clinical trials. These advancements not only enhance treatment outcomes but also attract investment from pharmaceutical companies looking to capitalize on the growing market. As technology continues to evolve, it is expected that the market will witness an influx of new products, further driving growth and adoption of RLT in India.

### Increasing Awareness of Radioligand Therapy

The growing awareness of radioligand therapy (RLT) among healthcare professionals and patients is a pivotal driver for the India Radioligand Therapy Rlt Market. Educational initiatives and seminars conducted by medical institutions and oncology associations have contributed to a better understanding of RLT's benefits. As a result, more patients are being referred for this innovative treatment, which is particularly effective for certain types of cancers. The market is projected to grow as awareness campaigns continue to proliferate, potentially leading to a rise in patient demand for RLT. This increased awareness is likely to enhance the overall acceptance of RLT as a viable treatment option, thereby expanding the market landscape in India.

### Rising Investment in Healthcare Infrastructure

The surge in investment in healthcare infrastructure in India is a significant driver for the India Radioligand Therapy Rlt Market. With the government and private sector focusing on enhancing healthcare facilities, there is a growing emphasis on integrating advanced treatment modalities like RLT. Hospitals and cancer treatment centers are increasingly equipped with the necessary technology and expertise to administer radioligand therapy. This investment not only improves access to RLT but also enhances the overall quality of cancer care in the country. As healthcare infrastructure continues to develop, it is anticipated that the market for RLT will expand correspondingly.

### Collaboration Between Research Institutions and Industry

The collaboration between research institutions and the pharmaceutical industry is fostering innovation in the India Radioligand Therapy Rlt Market. Partnerships aimed at developing new radioligands and improving existing therapies are becoming more common. These collaborations often lead to clinical trials that validate the efficacy of new treatments, thereby accelerating their entry into the market. Furthermore, such partnerships can facilitate knowledge transfer and resource sharing, which are vital for advancing RLT technologies. As these collaborations grow, they are likely to enhance the competitive landscape of the RLT market in India, driving further growth and development.

## Future Outlook

The India Radioligand Therapy Rlt Market is projected to grow at an 8.52% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and enhanced healthcare infrastructure.

**New opportunities:**

- Development of targeted radioligand therapies for rare cancers
- Expansion of radioligand manufacturing facilities in India
- Partnerships with healthcare providers for integrated treatment solutions

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing)

The India Radioligand Therapy (RLT) market displays a diverse application range, with oncology taking the largest share. This dominance is attributed to the increasing prevalence of cancer and the growing awareness and acceptance of radioligand therapies among oncology practitioners. In contrast, cardiology is emerging as a rapidly expanding segment. The shift towards minimally invasive procedures and the increasing incidence of cardiac ailments are driving growth in this category, making it a focal point for future investments in RLT.

Oncology (Dominant) vs. Cardiology (Emerging)

Oncology remains the dominant application in the India Radioligand Therapy market, driven by significant advancements in targeted cancer therapy. The targeted nature of radioligand therapy offers precision in treatment, providing an edge over traditional methods and catering to a broad range of cancer types. Meanwhile, cardiology is emerging as a noteworthy contender, propelled by innovations that enhance patient outcomes and safety. The integration of radioligands in cardiac treatments addresses complex cardiovascular conditions more effectively, indicating a promising future in this segment. As both applications evolve, they reflect the dynamic landscape of specialized therapies in the Indian healthcare sector.

### By End Use: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the India Radioligand Therapy RLT Market, hospitals currently hold the largest market share among the end-use segments, significantly contributing to the overall adoption of radioligand therapies. This segment benefits from extensive infrastructure, skilled personnel, and broader patient access, making it the primary choice for treatment. Following closely, diagnostic centers are emerging as a formidable player, capitalizing on the demand for precise diagnostic tools that enable targeted therapies in radioligand treatments.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals represent a dominant force in the India Radioligand Therapy RLT Market due to their comprehensive facilities and established systems integrating advanced therapeutic applications. They play a central role in patient management, offering both administration of therapies and immediate postoperative care. In contrast, research institutions emerge as pivotal players, driven by innovations in radioligand development and therapeutic research. These institutions facilitate advanced studies that lead to improved therapeutic outcomes and the introduction of new radioligands into clinical practice. Their collaborations with both industries and hospitals are vital for enhancing the overall market landscape.

### By Type of Radioligand: Alpha Emitters (Largest) vs. Beta Emitters (Fastest-Growing)

In the India Radioligand Therapy Market, Alpha Emitters dominate the market due to their high efficiency in killing cancer cells while minimizing damage to surrounding tissues. This segment accounts for a significant portion of market share, attributed to their ability to deliver targeted and effective treatment. Meanwhile, Beta Emitters are experiencing rapid growth, driven by advances in radiopharmaceuticals and increasing adoption of therapies for various types of tumors. Their market share is steadily increasing as more healthcare professionals recognize their benefits in treating specific malignancies.

Alpha Emitters (Dominant) vs. Beta Emitters (Emerging)

Alpha Emitters hold a dominant position in the India Radioligand Therapy Market due to their potent therapeutic effects and ability to target tumor cells effectively. These emitters are known for their short-range radiation, which allows for precision in treatment while sparing healthy tissue. On the other hand, Beta Emitters represent an emerging segment that is gaining traction rapidly. Their versatility in treating different cancers and lower production costs make them attractive options in the healthcare market. The increasing awareness of radioligand therapy is also promoting the growth of Beta Emitters, establishing them as a significant player in the industry.

### By Administration Route: Intravenous (Largest) vs. Oral (Fastest-Growing)

In the India Radioligand Therapy market, the administration routes of intravenous, oral, and intratumoral therapies showcase diverse market share dynamics. Intravenous administration stands as the largest segment, primarily due to its established efficacy and clinical preference among healthcare providers. On the other hand, oral administration is emerging as a competitive alternative, gaining traction for its ease of use and patient adherence, thus carving out a growing share in the market.

Intravenous (Dominant) vs. Oral (Emerging)

Intravenous administration of radioligand therapy remains dominant in India, favored for its rapid bioavailability and controlled dosing, which is critical in cancer treatment settings. This route allows for direct entry into the bloodstream, ensuring immediate therapeutic effects. Conversely, oral administration is rapidly emerging, appealing to patients for its convenience and non-invasive nature, which enhances compliance. This growing interest is propelled by ongoing research and development aimed at formulating effective oral radioligands. Moreover, the increasing focus on patient-centered care is driving a shift towards more user-friendly treatment options, making oral therapies a key player in the evolving landscape of radioligand therapy in India.

### By Target Disease: Prostate Cancer (Largest) vs. Neuroendocrine Tumors (Fastest-Growing)

In the India Radioligand Therapy (RLT) Market, Prostate Cancer holds a significant share, making it the largest segment. This prevalence is largely due to the increasing incidence of prostate-related health issues among the aging male population in India. Neuroendocrine Tumors, while smaller in market share, are emerging with notable momentum, driven by advancements in diagnostics and therapeutic techniques that enhance patient engagement and treatment outcomes.
The growth trends in this segment indicate a favorable trajectory for both Prostate Cancer and Neuroendocrine Tumors. Factors such as increasing awareness about early diagnosis, improved healthcare infrastructure, and a rise in clinical trials are propelling the market forward. The rising prevalence of these diseases, coupled with advancements in targeted therapies, is positioning RLT as a preferred treatment option in the Indian healthcare landscape.

Prostate Cancer (Dominant) vs. Neuroendocrine Tumors (Emerging)

Prostate Cancer is the dominant player in the India RLT Market, attributed to its significant patient population and favorable treatment responses to radioligand therapy. The focus on developing effective RLT options that target prostate-specific antigens has resulted in a shift towards personalized medicine. On the other hand, Neuroendocrine Tumors represent an emerging segment within the market. Their growth is enhanced by evolving treatment protocols and increased research into radionuclide therapy. The ongoing clinician awareness initiatives and technological advancements in radioligand therapy are contributing to its rising profile in the oncology space, aiming to improve therapeutic efficacy and patient survival rates.

## Competitive Benchmarking

The Radioligand Therapy Rlt Market in India is characterized by a dynamic competitive landscape, driven by increasing demand for targeted therapies and advancements in nuclear medicine. Key players such as Bharat Biotech (IN), Dr. Reddy's Laboratories (IN), and Novartis (CH) are actively shaping the market through strategic initiatives. Bharat Biotech (IN) focuses on innovation in radioligand development, aiming to enhance treatment efficacy and patient outcomes. Dr. Reddy's Laboratories (IN) emphasizes partnerships with research institutions to bolster its R&D capabilities, while Novartis (CH) is leveraging its global presence to expand its portfolio of radioligand therapies, indicating a trend towards collaboration and innovation in the sector.

The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive advancements in technology and treatment options, thereby shaping the competitive environment.

In December 2025, Bharat Biotech (IN) announced a collaboration with a leading research institute to develop a novel radioligand targeting prostate cancer. This strategic move is likely to enhance its product pipeline and position the company as a leader in innovative cancer therapies. The partnership underscores the importance of R&D in maintaining a competitive edge in the rapidly evolving market.

In November 2025, Dr. Reddy's Laboratories (IN) launched a new radioligand therapy for neuroendocrine tumors, marking a significant expansion of its oncology portfolio. This introduction not only diversifies its offerings but also reflects the company's commitment to addressing unmet medical needs in cancer treatment. The launch is expected to strengthen its market position and attract a broader patient base.

In October 2025, Novartis (CH) secured regulatory approval for its latest radioligand therapy, which targets specific [cancer biomarkers](https://www.marketresearchfuture.com/reports/cancer-biomarker-market-5378). This approval is pivotal, as it allows Novartis to capitalize on the growing demand for personalized medicine. The company’s ability to swiftly navigate regulatory pathways demonstrates its operational agility and commitment to innovation.

As of January 2026, current competitive trends in the Radioligand Therapy Rlt Market include a pronounced focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, fostering collaboration among industry players to enhance research and development efforts. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition suggests that companies prioritizing R&D and strategic partnerships will be better positioned to thrive in the future.

## Recent News & Developments

In recent months, the India Radioligand Therapy Market (RLT) Market has witnessed significant developments, particularly in the area of investment and collaboration among key players. The market is driven by increasing incidences of cancer and the growing adoption of targeted therapies. Bayer has been expanding its footprint in India, focusing on enhancing treatment options available through RLT. Elekta announced advancements in their systems, aiming to streamline RLT delivery, which reflects a growth trend in patient-centered therapeutic approaches.

Health organizations in India, including Bharat Serums and Vaccines, have been investing in Research and Development to innovate new radioligands for better effectiveness against malignancies.

The last two years saw notable market growth, with the valuation increasing due to the introduction of new therapies and technology by companies like Lantheus Medical Imaging and Novartis. In July 2023, there was a strategic partnership announcement between Curium and Ipsen aimed at expanding their product offerings in the Indian RLT market. Moreover, government initiatives supporting cancer research are further enhancing growth prospects for the RLT sector. Overall, these trends indicate a robust investment landscape and a strong competitive environment in India's Radioligand Therapy market.

## Report Scope

| MARKET SIZE 2024 | 0.407(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.445(USD Billion) |
| MARKET SIZE 2035 | 1.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.52% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bharat Biotech (IN), Dr. Reddy's Laboratories (IN), Laurus Labs (IN), Sun Pharmaceutical Industries (IN), Zydus Cadila (IN), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Siemens Healthineers (DE) |
| Segments Covered | Application, End Use, Type of Radioligand, Administration Route, Target Disease |
| Key Market Opportunities | Emerging demand for targeted cancer therapies drives growth in the India Radioligand Therapy Rlt Market. |
| Key Market Dynamics | Growing investment in Research and Development for Radioligand Therapy enhances treatment options in India's healthcare sector. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India Radioligand Therapy Rlt Market?**
A: The market valuation was 0.407 USD Billion in 2024.

**Q: What is the projected market size for the India Radioligand Therapy Rlt Market by 2035?**
A: The market is projected to reach 1.0 USD Billion by 2035.

**Q: What is the expected CAGR for the India Radioligand Therapy Rlt Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 8.52%.

**Q: Which applications dominate the India Radioligand Therapy Rlt Market?**
A: Oncology, with a valuation range of 0.25 to 0.6 USD Billion, appears to dominate the market.

**Q: What are the key end-use segments in the India Radioligand Therapy Rlt Market?**
A: Hospitals, with a valuation range of 0.2 to 0.475 USD Billion, are a key end-use segment.

**Q: What types of radioligands are utilized in the India market?**
A: Alpha emitters and beta emitters are significant, with valuations ranging from 0.1 to 0.35 USD Billion.

**Q: Which diseases are primarily targeted by radioligand therapy in India?**
A: Prostate cancer is a primary target, with a valuation range of 0.15 to 0.35 USD Billion.

**Q: Who are the leading players in the India Radioligand Therapy Rlt Market?**
A: Key players include Bharat Biotech, Dr. Reddy's Laboratories, and Novartis, among others.

**Q: What is the projected growth trend for the India Radioligand Therapy Rlt Market?**
A: The market is expected to grow steadily, reaching 1.0 USD Billion by 2035.

**Q: How does the market for radioligand therapy in India compare to other regions?**
A: While specific regional comparisons are not provided, the growth potential in India appears robust.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-radioligand-therapy-market-52095*